Premium Omega-3 EPA/DHA with Lignans, Krill and Astaxanthin

Quick summary

He Omega-3 Index The percentage of EPA + DHA in the erythrocyte membrane is one of the biomarkers with the best predictive power for cardiovascular mortality and cognitive decline. Maintaining it ≥8% requires sustained daily intake of EPA + DHA in bioavailable forms. Most of the market offers low absorption ethyl esters or subtherapeutic doses. The forms with the strongest evidence of elevated Omega-3 Index are re-esterified triglycerides y krill phospholipids.

Mechanism of action

• EPA (eicosapentaenoic acid): precursor of resolvins and protectins, active mediators of the resolution of inflammation (not just its suppression).
• DHA (docosahexaenoic acid): major structural component of neuronal and retinal membranes; critical for synaptogenesis and membrane fluidity.
• Anti-inflammatory eicosanoids: They compete with arachidonic acid for COX/LOX enzymes, shifting the balance towards resolving mediators.
• Endothelial function and triglycerides: documented reduction of plasma TG and improvement of FMD.
• Sesame lignans (when included): They inhibit hepatic Δ5-desaturase, redirecting precursors towards EPA.
• Astaxanthin (when included): lipophilic carotene that protects EPA/DHA from oxidation in vivo and ex vivo.

Clinical evidence

Robust evidence

• Triglyceride reduction: multiple meta-analyses with dose-dependent effect (≥2 g EPA+DHA/day).
• Cardiovascular mortalityREDUCE-IT (high-dose icosapent ethyl) and JELIS trials — reduction of events in patients with elevated TG.
• Omega-3 Index ≥8% associated with lower all-cause mortality (Framingham Cohort).

Plausible / suggested

• Support in major depression (modest but consistent effect).
• Reduction of cognitive decline in older adults with low Omega-3 Index.
• Improvement of dry eyes and tear membrane.
• Support in rheumatoid arthritis (reduction of morning stiffness and NSAIDs).

Speculative / preclinical

• Neuroprotection against Alzheimer's in animal models.
• Favorable modulation of intestinal microbiota.

Molecular form and bioavailability

The available forms, ordered by descending bioavailability:

• Re-esterified triglycerides (rTG): the most bioavailable; identical structure to natural fish.
• Phospholipids (krill): high bioavailability and oxidative stability; generally lower DHA content.
• Natural triglycerides (TG): acceptable; historical standard of unreseterified fish oil.
• Ethyl esters (EE): the cheapest way and the less bioavailable; predominant in low-cost products.

Oxidation is the Achilles' heel of omega-3: rancid oils can be pro-inflammatory. Search for products with low TOTOX (ideally <10) and incorporated antioxidants (astaxanthin, mixed tocopherols).

Limitations and what it DOES NOT do

• It is not an acute anti-inflammatory.The effect is built up over weeks to months as it integrates into cell membranes.
• It does not reverse established cardiovascular damage—it supports residual function and reduces events.
• Eating fatty fish 2–3 times/week may be equivalent; the supplement is backup.

Target population

• Adults with Omega-3 Index <8% measured (ideally, order the test).
• People who do not consume fatty fish 2-3 times per week.
• High triglycerides or metabolic syndrome.
• Pregnancy (DHA critical for fetal neurodevelopment) under medical indication.
• Athletes with high inflammatory loads and slow recovery.